TORL BioTherapeutics LLC is a clinical-stage biopharmaceutical company with the objective of developing novel, antibody-based therapeutics to transform the lives of cancer patients. Its lead candidate, TORL-1-23, is a CLDN6-directed ADC developed for patients across multiple cancer types. The Company also has two other clinical-stage programs; an ADC and mAb targeting CLDN 18.2. Additionally, TORL is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications with a high unmet medical need.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/13/23	$158,000,000	Series B	Alexandria Venture Investments Bristol Myers Squibb Cowen Healthcare Investments Deep Track Capital Goldman Sachs Asset Management Moore Strategic Ventures OCV Partners Perceptive Xontogeny Venture Fund Vertex Ventures	undisclosed